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Patients with peripheral artery disease (PAD) suffer from widespread atherosclerosis. Partly due to the
growing awareness of cardiovascular disease, the incidence of PAD has increased considerably during the
past decade. It is anticipated that algorithms to identify high risk patients for cardiovascular events
require being updated, making use of novel biomarkers. Advanced glycation end products (AGEs) are
moieties formed non-enzymatically on long-lived proteins under inﬂuence of glycemic and oxidative
stress reactions. We elaborate about the formation and effects of AGEs, and the methods to measure
AGEs. Several studies have been performed with AGEs in PAD. In this review, we evaluate the emerging
evidence of AGEs as a clinical biomarker for patients with PAD.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Peripheral artery disease (PAD) has become a global health
problem. Partly because of the growing awareness for cardiovas-
cular disease both among the general public and among health care
professionals, the reported prevalence of PAD did increase more
than 23% within a decade (2000 until 2010) [1]. Patients with PAD
do not only suffer from local symptoms, but they are also at
increased risk for cardiovascular events, such as myocardial
infarction, stroke and cardiovascular death. Therefore patients with
PAD are considered to qualify for secondary cardiovascular
prevention.
Within the group of patients with established cardiovascular
disease, including PAD, it remains a challenge to identify the veryucts; ABI, ankle-brachial in-
rtery disease; ELISA, enzyme-
escence; RAGE, receptor for
r Groningen, Department of
AA41, Hanzeplein 1, 9713 GZ
r Ireland Ltd. This is an open acceshigh risk patient in order to improve stratiﬁcation for secondary
cardiovascular prevention. An important drawback is that the
generally proposed cardiovascular risk estimators are designed to
identify those patients who classify for primary prevention. In fact,
updated algorithms that are employed in the current risk estima-
tors are insufﬁcient for this purpose. The primary prevention Fra-
mingham risk score and the Systematic Coronary Risk Evaluation
(SCORE) risk chart that are used frequently in the clinic, were
developed over 15 years ago [2,3]. In case of secondary cardiovas-
cular prevention, all patients are deemed at high risk, without a
generally accepted system for risk differentiation. Due to imple-
mentation of cardiovascular preventive medication such as lipid-
lowering drugs and antihypertensive drugs as secondary preven-
tion strategies, these established risk factors will be incorporated
into risk estimating mostly after being modiﬁed. For these reasons,
there is a clear need for updated and alternative risk prediction
models, especially in secondary prevention, whichmay also include
new risk markers. Therefore, an important challenge of current
research in cardiovascular disease, and in PAD in particular, is to
focus on ﬁnding better ways to predict cardiovascular events. A
potential way to achieve this is to search for new biomarkers to
identify patients with increased cardiovascular risk.
One group of biomarkers that are increasingly considered to bes article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
L.C. de Vos et al. / Atherosclerosis 254 (2016) 305e313306important to better identify high risk patients are advanced gly-
cation end products (AGEs). AGEs are formed by non-enzymatic
glycation or by oxidative reactions to form stable structures accu-
mulating on proteins with slow turnover, and are conceivably
involved in the process of aging [4]. Negative effects are the for-
mation of cross-links which cause stiffness of interstitial tissue,
mitochondrial dysfunction, and binding to the cellular receptors
such as receptor for AGE (RAGE) which may lead to cytokine
release. These effects modify pathways which contribute to
vascular dysfunction and accelerated development of atheroscle-
rotic processes. Increased levels of AGEs have been described in
several patient groups at increased cardiovascular risk, speciﬁcally
those with diabetes mellitus and renal insufﬁciency [5,6]. In fact,
increased AGE levels are associated with cardiovascular endpoints,
such as acute myocardial infarction, acute ischemic stroke, and
cardiovascular mortality [7e10].
Information on the role of AGEs in patients with PAD is scarce,
and this topic has not been reviewed before. In the current review,
we evaluate the role of AGEs in PAD. The review ﬁrst introduces the
biochemical background on AGEs, measurement methods, and its
association with atherosclerosis. Secondly, we will focus on clinical
studies available so far in patients with PAD in which AGEs in
plasma, skin and other tissues were measured.Fig. 1. Formation of advanced glycation end products (AGEs). Formation of AGEs by the
ROS, reactive oxygen species.2. Accumulation of AGEs
AGEs comprise a heterogeneous group and are formed by a com-
bination of glycation, oxidation, and/or carbonylation, which can be
divided into three distinct pathways, as outlined in Fig. 1 [11]. The
classical mechanism of AGE formation is the slow Maillard reaction
between glucose or reducing sugars and proteins. The interaction
between the carbonyl groups of reducing sugars and amino groups of
proteins results in the formation of a Schiff base within a few hours.
Intramolecular rearrangementof the Schiff base results inmore stable
Amadori products. Glycatedhemoglobin is an example of anAmadori
product that is widely used in clinical practice for diagnosis and
regulation of diabetes mellitus. The slow process of oxidation of the
Amadori products lead to reactive carbonyl compounds and subse-
quently to the formation of AGEs within weeks to months. The best-
known AGEs derived from this glycoxidation process are pentosi-
dine, Nε-carboxymethyl-lysine (CML) and glucosepane [12].
Other, and much faster evolving, processes involving AGE for-
mation are lipid peroxidation and the glycolysis pathway. In the
lipid peroxidation pathway, reactive oxygen species (ROS) alter
lipids into reactive carbonyl compounds under inﬂuence of oxida-
tion. This formation results into AGEs or advanced lipid end prod-
ucts (ALEs), for example malondialdehyde [11]. This reaction takes
place both intracellularly and extracellularly.three different pathways: Maillard reaction, lipid peroxidation and glycolysis pathway.
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into reactive carbonyl compounds, of which the best-known is
methylglyoxal. The chemical reaction between reactive carbonyl
compounds and proteins can result in AGEs. An example of AGEs
formed by this pathway is methylglyoxal-derived hydro-
imidazolone (MG-H1).
Besides endogenous formation of AGEs, absorption of exoge-
nous AGEs occurs by two mechanisms. Firstly, accumulation of
AGEs occurs by inhalation of tobacco smoke. Tobacco smoke con-
tains highly reactive glycation products which rapidly form AGEs
in vitro and in vivo. Serum AGEs are signiﬁcantly elevated in
smokers who smoke at least a package a day as compared to non-
smokers [13]. Secondly, intake of high-AGE food products may lead
to an increase of AGEs. The temperature at which food products are
prepared is of major importance for the amount of AGEs, with oven
frying as most severe inducer [14]. Approximately 10% of the AGEs
from food products and beverages are absorbed from the gastro-
intestinal tract into the blood [15]. For example, serum CML
increased after a 6-week high-AGE diet and decreased in low-AGE
diet in patients with diabetes mellitus [16].Fig. 2. Measurements of advancedThe ﬁnal mechanism which affects the exposure to and accu-
mulation of AGEs is the clearance of the kidney and metabolism by
the liver. Increased level of AGEs can be found in patients with
either renal or liver failure [17,18]. This is also in part attributable to
increased production of oxidative stress in these diseases, which
stimulates formation of AGEs. However, plasma pentosidine
decreased with different types of dialysis in renal failure [17].
Furthermore, plasma pentosidine decreased to 80% six months af-
ter renal transplantation, and plasma CML decreased to 50% three
years after liver transplantation [17,19]. These ﬁndings indicate that
the accumulation of AGEs in the blood is at least in part reversible in
the context of improvement of kidney and liver function.
3. Measurement of AGEs
For appropriate assessment of AGEs levels, the biological sample
material as well as the method to measure AGEs are important.
Firstly, several methods have been developed to measure AGEs in
different body compartments, including blood, urine, and tissue
(see Fig. 2). Blood and urine samples can obviously be obtainedglycation end products (AGEs).
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lularly, but are also bound intracellularly, or in interstitial tissues.
For these reasons, circulating AGEs, especially in plasma, do not
sufﬁciently reﬂect the AGE amount in tissues [20]. In addition, as
stated above, the amount of plasma AGEs is affected by its clearance
by kidney and liver. Therefore, concentrations of various AGEs in
plasma may ﬂuctuate over time.
The other possibility is to measure AGEs in tissue. An issue of
particular importance is the turnover time of tissues. AGEs cross-
linked to collagen or other proteins in interstitial compartments
are considered to remain linked during the lifetime of the speciﬁc
tissue. For example, articular cartilage collagen is thought to have
an extremely long half-time, which was calculated to be as high as
117 years [21]. AGEs linked to eye lens proteins remain there life-
long, and accumulate already from the preconceptual period on.
Therefore, these AGEs are considered to represent an estimate of
long-termmetabolic memory. However, most tissue material is not
easy to obtain. A relatively easy tissue to acquire is skin tissue,
which was calculated to have a half-life of 14.8 years [21]. For this
reason, it has been used in early studies on the role of AGE, for
example in patients with type 1 diabetes [22].
Several techniques nowavailable to measure AGEs are described
in Table 1 [23]. Traditionally, quantitative measurements of AGEs
were performed with enzyme-linked immunosorbent assays
(ELISA). However, experts in the ﬁeld state that for quantitative
analysis, ELISA has limited speciﬁcity and reproducibility [24].
Furthermore, ELISA kits do not measure the difference between
protein-bound and free circulating AGEs. Therefore, studies which
use this technique, especially when employing older ELISA kits,
should possibly be interpreted with caution. High performance and
ultra-high performance liquid chromatography methods, most
combined with mass spectrometry, have become the technique of
choice to measure both free as well as protein-bound AGEs. A
method for localization of AGEs is immunohistochemistry, but this
technique is not frequently used.
In addition, the noninvasivemethod skin autoﬂuorescence (SAF)
has been designed to assess the AGEs of the skin with the so-called
AGE Reader™ (DiagnOptics Technologies BV, Groningen, the
Netherlands). Eye lens autoﬂuorescence has also recently been
proposed for assessing lens AGE accumulation as tool for diabetes
screening (Clearpath DS, Freedom Meditech, USA). Some AGEs
respond to ultraviolet light by emitting ﬂuorescent light with
another wavelength. Meerwaldt et al. showed a strong correlation
between SAF and the ﬂuorescent AGE pentosidine as well as theTable 1
Advantages and disadvantages of techniques to measure AGEs.
Technique Material Advantages
Enzyme-linked immunosorbent
assay (ELISA)
Liquids including blood and urine
and tissue
- Suitable f
(Ultra-)High performance liquid
chromatography
Liquids and tissue - Accurate
- Both free
- Measurem
Immunohistochemistry Tissue - Localizati
Skin autoﬂuorescence Skin - Noninvas
- Fast tech
- Point of c
Eye lens autoﬂuorescence Eye lens - Noninvas
- Fast tech
AGEs, advanced glycation end products.non-ﬂuorescent AGE CML and Nε-carboxyethyl-lysine (CEL) in the
dermal layer of the skin [25]. Since the device uses light to detect
AGEs, it is difﬁcult to measure patients with a very dark skin, due to
absorption of both the incoming light and the ﬂuorescent light.
Another limitation of the AGE Reader™ is the effect of skin cream
on SAF measurements. Especially self-browning cream and sun
blocker cream block the incident light and cause unreliable SAF
measurements [26].4. Vascular effects of AGEs
AGEs are harmful via two main pathogenic pathways (Fig. 3).
Firstly, several AGEs have the potential to form cross-links which
results in impaired protein function and turnover, and in increased
tissue stiffness as a consequence of collagen and elastin cross-
linking. Secondly, AGEs may also bind to cell membrane receptors
resulting in release of pro-inﬂammatory cytokines, thereby
enhancing inﬂammatory reactions.
Speciﬁc AGEs, such as pentosidine, form cross-links between
proteins [27]. Cross-links between and within collagen and elastin
ﬁbers result in loss of distensibility and strength, and hence
induce arterial stiffness [28]. Results from the Maastricht Study
showed a strong association between AGEs and pulse wave ve-
locity as a marker for arterial stiffness. The results showed that
plasma protein-bound pentosidine, as well as SAF was positively
associated with carotid-femoral pulse wave velocity in 862 pa-
tients with normal glucose metabolism, impaired glucose meta-
bolism and type 2 diabetes mellitus [29]. In contrast, plasma CML
and CEL were not associated with pulse wave velocity in the latter
study. Hofmann et al. showed that tissue AGEs, derived from
venous graft material, as well as SAF, were positively associated
with pulse wave velocity in patients with coronary artery disease
[30]. In addition, stiffness of the heart causes diastolic dysfunc-
tion. Several parameter of diastolic dysfunction, measured with
echocardiography (e.g. E/A ratio), are associated with both serum
AGEs and SAF [31,32].
Secondly, AGEs promote cellular stress responses by engage-
ment to receptors on the cell membrane. The binding of AGEs to
RAGE results in intracellular activation of nuclear transcription (NF-
kB) factor [33]. NF-kB induces the release of several adhesion
molecules and pro-inﬂammatory cytokines such as vascular cell
adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1
(ICAM-1), and interleukin-6. Morita et al. showed that ROS and
TNF-a were elevated after stimulation of human aortic endothelialDisadvantages
or large number of measurements - Limited speciﬁcity, and reproducibility
- No differentiation between protein-
bound and free circulating AGEs
- Lack of standard ELISA kits for AGEs
and precise measurements
as well as protein-bound AGEs
ent of speciﬁc AGEs
- Expensive due to speciﬁc equipment and
dedicated personnel
on of AGEs in tissue - Invasive biopsies needed before analysis
- Lack of standardized antibodies for AGEs
ive
nique (within seconds)
are testing
- Difﬁcult to measure patients with a very
dark skin
- False elevated levels after use of self-
browning cream and sun blocker cream
block
ive
nique (within seconds)
- Limited clinical research
Fig. 3. Vascular effects of advanced glycation end products (AGEs). CAC, coronary artery calcium; FDG-PET, 18F-ﬂuorodeoxyglucose-positron emission tomography; IMT, intima-
media thickness; PWV; pulse wave velocity; RAGE, receptor for advanced glycation end products.
L.C. de Vos et al. / Atherosclerosis 254 (2016) 305e313 309cells with AGE, which suggests that NF-kB is involved in this re-
action [34]. Both TNF-a and ROS induce endothelial dysfunction
and, therefore, stimulate the atherosclerotic process.
Besides these two pathogenic pathways, there is also evidence
in support of local effects of AGEs on plaques in the arterial wall.
AGE precursors are associated with macrophage apoptosis, causing
rupture-prone atherosclerotic plaques [35]. In 75 carotid artery
plaques, increased levels of MG-H1 and CML were found in histo-
logical identiﬁed rupture-prone plaques versus intermediate and
stable plaques [35]. Furthermore, the latter study showed that the
AGE precursor dicarbonyl methylglyoxal induced apoptosis of
macrophages in vitro. Therefore, AGEs and their precursors are
thought to be associated with unstable plaques, which in case of
rupture provoke cardiovascular events.
The vascular effects of AGE are clinically relevant as shown by
the associations between AGEs and atherosclerotic parameters,
such as coronary artery calcium (CAC) score, intima-media thick-
ness (IMT), and 18F-ﬂuorodeoxyglucose-positron emission tomog-
raphy (FDG-PET) (Fig. 3). In a cross-sectional study including 275
Japanese subjects, a positive association was found between
glyceraldehyde-derived AGEs, measured with ELISA, and IMT, as
well as between glyceraldehyde-derived AGEs and vascular
inﬂammation, measured by FDG-PET [36]. Our research group has
found that SAF is associated with IMT in 59 subjects without dia-
betes mellitus and cardiovascular disease, as well as with CAC score
in patients with subclinical atherosclerosis (n ¼ 67) and PAD
(n ¼ 60) versus controls (n ¼ 96) [37,38].5. AGEs in PAD
As yet, six observational studies have been published in patients
with PAD evaluating levels of AGEs measured in blood or with SAF
(Table 2). Lapolla et al. were the ﬁrst to show elevated serum AGEs
including pentosidine in 33 type 2 diabetic patients with PAD
versus 66 type 2 diabetic patients without PAD and 20 healthy
control subjects [39]. All participants were evaluated by echo
Doppler, and in patients with an ankle-brachial index (ABI) <0.90,
PAD was conﬁrmed by abnormal plethysmography. Serum AGEs
were measured with ELISA and pentosidine was measured with
liquid chromatography. In this study, ABI was inversely correlated
with AGE and pentosidine in the diabetic patients. Obviously, these
results were only correlations, and no multivariable models were
performed in which could be corrected for cardiovascular risk
factors. Furthermore, as mentioned above, results obtained from
earlier available ELISA kits should be interpreted with caution.
Our research group found an association with SAF in a small
subgroup of patients with both carotid artery stenosis and PAD
versus carotid artery disease only [40]. This study was designed to
detect the differences between patients with carotid artery stenosis
and age- and sex-matched control subjects. Indeed, SAF was higher
in patients with carotid artery stenosis. However, excluding the
patients with PAD resulted in the loss of signiﬁcant differences
between carotid artery stenosis and control subjects. Determinants
of SAF were age, smoking, diabetes mellitus, eGFR, and PAD. Lack of
performing carotid duplex ultrasound examinations in control
Table 2
Overview studies performed in patients with peripheral artery disease.
Study Type of AGE
measurement
Design Number of
participants
Outcome Data
Lapolla et al. [39] Serum AGE þ
pentosidine
Case-control study N ¼ 33 PAD þ DM
N ¼ 66 DM
N ¼ 20 controls
Highest serum AGEs and
pentosidine in PAD
Noordzij et al. [40] SAF Case-control study N ¼ 14 PAD þ CAS
N ¼ 42 CAS
N ¼ 56 controls
Highest SAF in PAD
Liu et al. [41] SAF Cross-sectional study N ¼ 94 PAD þ DFU
N ¼ 24 DFU
SAF is associated with the
presence of PAD
OR
5.98E9; 95% CI 2.35E5e1.52E14
de Vos et al. [42] SAF Case-control study N ¼ 492 PAD
N ¼ 164 controls
SAF is associated with the
presence of PAD
OR per unit increase of SAF
2.47; 95% CI 1.66e3.69
de Vos et al. [43] SAF Cohort study N ¼ 252 All-cause mortality and fatal
and nonfatal MACE
HR per unit increase of SAF
1.63; 95% CI 1.13e2.34
1.50; 95% CI 1.04e2.17
de Vos et al. [44] SAF Cohort study N ¼ 252 Amputation sHR per unit increase of SAF
2.72; 95% CI 1.38e5.39
Catalano et al. [45] sRAGE Case-control study N ¼ 201 PAD
N ¼ 201 controls
sRAGE is lower in PAD versus
controls
Shiotsu et al. [46] Ligand for RAGE
S100A12
Case-control study N ¼ 26 PAD þ ESRD
N ¼ 126 ESRD
S100A12 was associated with
the presence of PAD
OR
5.71; 95% CI 1.29e25.30
Malmstedt et al. [47] Ligand for RAGE
S100A12 þ RAGE score
Cohort study N ¼ 68 Major amputation or death HR S100A12 above 75th percentile
vs. below
2.58; 95% CI 1.05e6.35
HR per unit increase in RAGE score
2.23; 95% CI 0.85e5.88
Malmstedt et al. [47] Ligand for RAGE
S100A12 þ CML þ
esRAGE
Case-control study N ¼ 68 PAD
N ¼ 30 controls
Highest levels of S100A12 and
CML in PAD, while esRAGE was
not different
Liu et al. [48] sRAGE RCT N ¼ 45 cilostazol
N ¼ 45 placebo
sRAGE signiﬁcantly increased in
the treatment group
All odds ratios and hazard ratios represent the results of a multivariable analysis.
AGE, advanced glycation end products; DFU, diabetic foot ulcer; DM, diabetes mellitus; CML, Nε-carboxymethyl-lysine; esRAGE, endosecretory RAGE; ESRD, end-stage renal
disease; HR, hazard ratio; OR, odds ratio; PAD, peripheral artery disease; RCT, randomized controlled trial; SAF, skin autoﬂuorescence; sHR, subproportional hazard ratio;
sRAGE, soluble receptor for AGE.
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tween the subgroup of carotid artery stenosis only versus control
subjects, since the control subjects might be suffering from
asymptomatic atherosclerotic disease. Neither the degree of ste-
nosis nor differences between asymptomatic and symptomatic
carotid stenosis were attributable to differences in SAF. Although
the evidence for the association between PAD and SAF in this report
is limited due to the low number of patients (n ¼ 14, 25%), this
study lends support to the hypothesis that SAF is associated with
PAD.
Another cross-sectional study which showed an association
between SAF and PAD in a subgroup was performed in Chinese
patients with diabetic foot ulcers. A total of 94 (80%) of these pa-
tients had PAD [41]. In this study, the presence of PAD was posi-
tively and independently associatedwith age, glycated hemoglobin,
and SAF. This study was designed to evaluate the role of SAF in
patients with diabetic foot ulcers. Strong points of this study are
that data of micro- and macrovascular complications were
described extensively. Furthermore, multivariable analyses were
performed for all micro- and macrovascular comorbidity individ-
ually. Unfortunately, this study was not designed as a case-control
study with PAD patients. Therefore, this is underscored by the high
number of patients with PAD. Therefore, this study is not appro-
priate for determining that SAF is increased in PAD compared to
controls.
The largest cross-sectional study which evaluated the associa-
tion between SAF and PAD was performed by our research group. A
total of 492 patients with PAD was compared to age and diabetes
mellitus matched control subjects (n ¼ 164) [42]. Strict inclusion
and exclusion criteria were used. In case of an ABI < 0.90, the
diagnosis of PAD was established using duplex ultrasound,computed tomographic angiography, magnetic resonance angiog-
raphy, or catheter angiography. Patients with end-stage renal dis-
ease (eGFR < 15 mL/min per 1.73 m2), recent myocardial infarction
or stroke, and patients with an organ transplantation were
excluded. SAF was higher in patient with PAD versus control sub-
jects. In a logistic regression model including all patients, SAF was
still signiﬁcantly associated with PAD after adjustment for cardio-
vascular risk factors and comorbidity, with an odds ratio of 2.47 per
unit increase of SAF; 95% conﬁdence interval 1.66e3.69. Remark-
ably, SAF was not associated with ABI. This study was designed as a
case-control study to evaluate whether SAF was increased
compared to controls. Due to the strict inclusion and exclusion
criteria, combined with the matching procedure and the multi-
variable regression analyses, this study was able to provide strong
evidence for an increased SAF in patients with PAD compared to
controls.
A total of 252 patients included in the latter study, could be
followed for 5 years. Both cardiovascular endpoints as well as local
outcome were evaluated. First, the endpoints all-cause mortality
and fatal and nonfatal major adverse cardiovascular events
(nonfatal MACE, deﬁned as myocardial infarction and stroke) were
analyzed. A total of 62 subjects (25%) died and fatal and nonfatal
MACE occurred in 62 patients (25%) [43]. SAF was associated with
all-cause mortality, also after adjustment for possible confounders
(adjusted hazard ratio: 1.63 per unit increase of SAF; 95% conﬁ-
dence interval 1.13e2.34). SAF was also associated with fatal and
nonfatal MACE, even after adjustment for confounders. A limitation
in this study is that no blood, urine, or tissue was obtained from the
patients at inclusion. Therefore, AGEs were only estimatedwith SAF
and not directly measured in blood, urine, or tissue. Furthermore,
no parameters for oxidative stress and inﬂammation were
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biomarker for cardiovascular events in patients with PAD, irre-
spective from risk factors such as age.
The second reported endpoint of local outcome was amputation
during follow-up of 5 years. SAF was positively associated with
amputation, analyzed with competing risk regression analysis with
death as competing risk, subproportional hazard ratio from the
multivariable analysis was 2.72; 95% conﬁdence interval 1.38e5.39
[44]. In addition, a prediction model was tested for SAF. Therewas a
positive interaction of SAF with Fontaine classiﬁcation resulting in
an area under the curve of 0.83; 95% conﬁdence interval 0.74e0.92
for future amputation. A subgroup analysis was performed in pa-
tients with Fontaine I or II at inclusion. In this subgroup, SAF was
the only predictor of amputation with a subproportional hazard
ratio of 4.05; 95% conﬁdence interval 2.09e7.83. SAF was not
associated with intervention for PAD. This is the ﬁrst model which
demonstrates SAF as a useful marker in a prediction model for
patients with PAD.
The last two studies are important because these are the ﬁrst
examples that SAF may have added value for risk differentiation in
secondary cardiovascular risk prediction in patients with known
PAD. These results correspond with previous studies in which SAF
was shown to differentiate risk and thereby add clinically useful
information for cardiovascular risk prediction in other high car-
diovascular risk groups with type 2 diabetes or with renal failure
[9,10]. The consequence of such a risk differentiation within a high
risk group may be translated into targeted intensiﬁcation of sec-
ondary preventive treatment.
6. RAGE in PAD
Another indirect approach to evaluate the AGEs-RAGE pathway
is by measuring RAGE. Four research groups obtained information
about soluble RAGE (sRAGE), endosecretory RAGE and S100A12, a
ligand for RAGE in patients with PAD.
One study performed a case-control study and compared sRAGE
in patients with PAD (n ¼ 201) versus controls (n ¼ 201). sRAGE,
measured by ELISA, was signiﬁcantly lower in patients with PAD
versus control subjects [45]. sRAGE is supposed to operate as a
decoy for circulating AGEs, thereby preventing the interaction of
AGE with RAGE, and reducing inﬂammatory and oxidative stress
reactions. A strength of this study is the selection of control sub-
jects; all of them were screened for PAD with ABI measurement. A
limitation of this study is the selection of only Caucasians without
diabetes mellitus. Since diabetes mellitus is a strong risk factor for
PAD, these patients do not reﬂect typical PAD patients. Further-
more, this study used an older ELISA kit, and therefore these results
should be interpreted with care. Although a multivariable logistic
regression analysis for the presence of PAD was performed, the
results of the role of sRAGE with correction for risk factors was not
shown.
Shiotsu et al. showed that PAD patients with end stage renal
disease (ESRD) on hemodialysis had increased plasma levels of
S100A12, a ligand for RAGE, versus ESRD patients without PAD [46].
Plasma S100A12 and ABI were associated with the occurrence of
PAD. A limitation of this study is the low number of PAD patients
(n ¼ 26). A plausible explanation might be due to the deﬁnition for
diagnosis of PAD. In this study, PAD was deﬁned by clinical symp-
toms or a history of PAD. Asymptomatic patients were therefore not
included. Furthermore, the more easily obtainable ABI measure-
ment was not used, because of the possibility of overestimation due
to increased arterial media sclerosis in these patients.
Malmstedt et al. published a combined case-control and pro-
spective cohort study. In the case-control study, plasma CML and
S100A12 were elevated in PAD patients compared to age and sex-matched healthy controls without cardiovascular disease or dia-
betes mellitus, while endosecretory RAGE, a scavenger for AGE
which prevents AGE-RAGE interaction, was not increased in PAD
patients [47]. No additional multivariable models were performed
in the case-control study. In the prospective cohort study, S100A12
and a RAGE score, which combines plasma CML, S100A12 and
esRAGE, were tested as a biomarker for the primary composed end
point major amputation and death. Indeed, both S100A12, as well
as the RAGE score, were associated with this end point, while only
S100A12 remained signiﬁcant after correction for cardiovascular
risk factors [47]. A limitation of this multivariable regression model
is that although adjustments were made for age and diabetes
mellitus, other important risk markers for AGEs such as smoking
and renal function were not included into the analysis. In addition,
also AGE and CML was measured with immunohistochemical
staining in venous tissue of PAD patients obtained from infrain-
guinal bypass surgery.
In contrast to the observational studies on the relations with
RAGE, Liu et al. performed an open randomized-controlled trial in
PAD patients with diabetes mellitus. This study showed effects of
the antiplatelet/antithrombotic agent, cilostazol, on ABI. After 52
weeks of active treatment ABI increased compared to placebo [48].
Plasma sRAGE was increased in the treatment group, but not in the
placebo group. The increased sRAGE levels coincided with lower
hsCRP, sVCAM and E-selectin levels in concert with the concept that
sRAGE serve as a scavenger for circulating AGEs, thereby decreasing
the detrimental effect of AGEs. In a multivariable linear regression
analysis, sRAGE was the only signiﬁcant determinant for change of
ABI. A limitation of this study was that PAD only was determined
with ABI, and no angiography or magnetic resonance angiography
were used. Although this observation would suggest that sRAGE
might have a role as marker of an intervention response, this
observation needs conﬁrmation in other intervention studies.
7. Therapeutic targets
In addition to the use of AGEs as a biomarker, lowering of AGEs
might be a therapeutic target. Several studies were performed
targeting reduction of AGE formation, as well as breakdown of
existing AGEs. However, both, the AGE inhibitor, aminoguanidine,
and the AGE breaker alagebrium were not safe or efﬁcient enough
to be introduced in clinical practice [49]. Furthermore, the study
arm of the high dose RAGE inhibitor PF-04494700 was terminated
due to adverse events (mental confusion and falls) in a randomized
controlled trial in patients with Alzheimer disease [50]. The low-
dose study arm resulted in a decreased decline of the cognitive
function of the patients. These results should be interpreted with
caution due to the high dropout and discontinuation of the study.
Although there are so far limited pharmacological possibilities
to effectively reduce AGEs accumulation or their vascular effects,
patients are able to inﬂuence their AGE levels by adjusting their
lifestyle. As described earlier, tobacco increases the AGE accumu-
lation to a serious degree. Furthermore, further studies are war-
ranted to assess the effects of lowering dietary intake of AGEs by
PAD patients. A randomized cross-over designed trial is currently
being performed in non-diabetic adults with a 2-week period of
high and low AGE diet [51].
8. Future perspectives
Before AGEs might be considered for adding predictive infor-
mation to cardiovascular risk prediction, there are several steps to
take. First, the association between SAF and cardiovascular end-
points are generated from one cohort study of patients with PAD.
Therefore, these results should be repeated and conﬁrmed in other
L.C. de Vos et al. / Atherosclerosis 254 (2016) 305e313312cohorts, and other research groups.
Second, the majority of the studies were performedwith the use
of the AGE Reader™. A case-control study with serum AGEs,
measuredwith liquid chromatography, should identify whether the
results from Lapolla et al. are reproducible [39]. Although the AGE
Reader™ has been validated with skin biopsies, it would be of in-
terest to know whether SAF correlates with AGEs in the arterial
wall. It is likely that AGEs of arterial tissue and SAF correlate, since
Hofmann et al. showed that SAF was strongly correlated to AGEs in
cardiac tissue from patients with coronary artery disease [52].
Finally, the paucity of effective pharmaceutical or lifestyle in-
terventions aimed at reducing AGE accumulation or effector path-
ways, limits the possibility for targeted intervention. As for the
broader use of SAF or other AGE markers for risk prediction, more
evidence is also needed that patients reclassiﬁed by SAF to higher
cardiovascular risk, will beneﬁt from intensiﬁed treatment. Espe-
cially in PAD patients considered at highest risk for amputation as
determined by SAF, beneﬁt from earlier surgical treatment should
be ascertained in new studies.
9. Conclusion
Given the increasing prevalence of PAD worldwide, new bio-
markers are required to better identify patients at highest risk.
Several studies show a positive association between AGEs and PAD.
The majority of the available studies were performed with the use
of the AGE Reader™. SAF, as a measure for skin AGEs, was found to
be useful to identify patient at highest risk for local and cardio-
vascular endpoints. Future studies are necessary to evaluate
whether these high risk patients beneﬁt from intensiﬁed
treatment.
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